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Postmarketing drug surveillance is a crucial aspect of the clinical research activities in pharmacovigilance and pharmacoepidemiol-
ogy. Successful utilization of available Electronic Health Record (EHR) data can complement and strengthen postmarketing safety
studies. In terms of the secondary use of EHRs, access and analysis of patient data across different domains are a critical factor;
we address this data interoperability problem between EHR systems and clinical research systems in this paper. We demonstrate
that this problem can be solved in an upper level with the use of common data elements in a standardized fashion so that clinical
researchers can work with different EHR systems independently of the underlying information model. Postmarketing Safety Study
Tool lets the clinical researchers extract data from different EHR systems by designing data collection set schemas through common
data elements. The tool interacts with a semantic metadata registry through IHE data element exchange profile. Postmarketing
Safety Study Tool and its supporting components have been implemented and deployed on the central data warehouse of the
Lombardy region, Italy, which contains anonymized records of about 16 million patients with over 10-year longitudinal data on
average. Clinical researchers in Roche validate the tool with real life use cases.
1. Introduction
It is a well-accepted fact that, due to the limited scope
and duration of clinical trials, drugs may still have serious
side effects, adverse drug reactions (ADRs), after they are
marketed. Postmarketing drug surveillance systems have
been in place in order to analyze additional information
about a drug’s safety, efficacy, and optimal use to capture such
ADRs. During the last decades, postmarketing activities in
pharmacovigilance have largely depended on spontaneous
case reports, which is still the case unfortunately. There are
certain limitations on surveillance activities with sponta-
neous report data [1–4]. Postmarketing surveillance is also
of vital importance for pharmacoepidemiology, especially for
evidence development about effectiveness, safety, and quality
of drugs in terms of ADRs [5, 6].
At present, postmarketing drug surveillance is largely
being carried out with traditional methods for both phar-
macovigilance and pharmacoepidemiology. In pharmacovig-
ilance, there is active research on data mining algorithms
[7] running on spontaneous report databases. On the other
side, dedicated cohort and case-control studies are being per-
formed within pharmacoepidemiological research. Although
these traditional methods are currently dominant, a new
research area that uses the already available electronic health
data for clinical research purposes is emerging, which is
referred to as the secondary use of Electronic Health Records
(EHRs). EHRs provide a huge, but still underutilized, source
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of information on the real world use of drugs for observa-
tional studies. Although EHRs are primarily designed for
patient care, they also contain a broad range of clinical
information highly relevant to surveillance studies. EHR data
available in clinical care systems can clearly complement and
strengthen existing postmarketing safety studies [3, 8, 9].
Relative to spontaneous reports, EHRs cover extended parts
of the underlying medical histories, include more complete
information on potential risk factors, and are not restricted
to patients who have experienced an adverse drug reaction.
Successful utilization of available EHRs for clinical
research in terms of access, management, and analysis of
patient data within and across different functional domains
is a critical factor in terms of secondary reuse [9]. In line
with this vision, there are important efforts for building
large data pools from the EHRs to benefit from the available
longitudinal observational data. The Sentinel Initiative of the
U.S. Food and Drug Administration (FDA) aims to build
a distributed network for active postmarketing surveillance
for drug safety in the USA [10, 11]. The Observational Med-
ical Outcomes Partnership (OMOP) is another important
initiative targeting a similar objective for improvements in
postmarket drug monitoring [12]. There are several other
pharmacoepidemiological databases such as the Clinical
Practice Research Datalink (CPRD) [13] which is based on
the General Practice Research Database (GPRD) experience
in the UK and The Health Improvement Network (THIN)
database containing longitudinal medical data [14]. As a
natural result, datamining on such national and international
data pools appears as a new research area for signal detection
and safety monitoring [3, 4].
The objective of the aforementioned initiatives is to use
the available EHR data held by multiple different systems
for clinical research purposes (mainly for postmarketing
surveillance, comparative effectiveness research, and evi-
dence development). In addition to the distributed archi-
tecture of the Sentinel Initiative, recent research projects
like SALUS (Scalable, Standard based Interoperability Frame-
work for Sustainable Proactive Post Market Safety Studies)
[8], TRANSFoRm (Translational Research and Patient Safety
in Europe) [15], and EHR4CR (Electronic Health Records
for Clinical Research) [16] address the different levels of the
interoperability problem between the clinical research and
patient care domains with a distributed perspective.
Current research on postmarketing surveillance for phar-
macovigilance and pharmacoepidemiology tries to unify the
available EHR data on a common information model. Most
of the time, this forces the EHR systems to implement the
necessary adapters for transforming data into the defined
common model and persist in a separate database. Either
distributed or not, analyses on longitudinal EHR data require
clinical researchers to implement the designed algorithms
and build methods according to the predefined data model
of the database that they are working on. On the other
hand, some approaches transform the query to the native
data model at each transaction. It is an experienced fact
that data and processing requirements of different areas of
clinical research change in time while the quality, quantity,
and availability of EHR data on patient care side increase.
In parallel with this, new initiatives propose new common
data models into which collaborating EHR sources have to
transform and transfer data, regardless of the system’s nature.
The literature exemplifies this situation clearly.
Vaccine SafetyDatalink [17] is an early initiative for trans-
forming EHR data for postmarketing safety surveillance of
vaccines. FDA’s Sentinel Initiative and theMini-Sentinel pilot
system [10, 11] are one of the latest and important efforts for
postmarketing surveillance, built on the experiences of Vac-
cine Safety Datalink. Mini-Sentinel builds a distributed sys-
tem to answer safety queries of clinical researchers through
a common information model. OMOP [12] introduces its
own common data model (CDM) to transform EHR data.
Informatics for Integrating Biology and the Bedside (i2b2)
[18] is another parallel effort with similar objectives that
exposes its own common information model. CPRD [13] is
a European example of the latest pharmacoepidemiological
databases and there are several ongoing projects supported
by European Medicines Agency and European Commission
using a common information model for surveillance activi-
ties. The fact is that those common information models are
not so “common”; they are only used within the boundaries
of the associated initiatives and projects.
In this paper, we address the heterogeneity problem
among common data models for clinical researchers who
work on EHR data for postmarketing surveillance stud-
ies. We show that this problem of interoperability can be
solved in an upper level with the use of common data
element (CDE) phenomenon [19]. If the applications share
the machine-processable definitions of the data elements and
there are established links between data elements of different
domains (i.e., clinical research and patient care domains),
this can be used to facilitate automatic access to data across
different domains. Hence, in the context of postmarketing
surveillance, uniform observational analysis methods can be
designed and implemented independently of the underlying
data model, whether the source is a pharmacoepidemiologi-
cal database or directly a hospital information system.
In the light of the common data element based interoper-
ability approach, we design and implement the Postmarket-
ing Safety Study Tool (PMSST) which can extract any needed
information from a patient record after it is retrieved as a
result of an eligibility query or it is directly accessed from the
EHR database within a data mining routine. Our design is
built upon the notion of CDEs and makes use of a Semantic
Metadata Registry (MDR) to retrieve data element definitions
and use their extraction specifications to access data [19, 20].
With the use of the extraction specifications, PMSST lets the
researcher define what needs to be extracted from the patient
records with the help of the abstract CDEdefinitions accessed
from a semantic MDR [19]. With this dynamic behavior,
the researcher writes her methods on the schema/template
which will be created based on the data elements that she
manipulates. With the help of the underlying interoperability
framework [19], postmarketing surveillance methods do not
have to be restricted to the data model of an EHR source.
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2. Materials and Methods
The tool that we introduce in this paper has been built
within the SALUS interoperability framework. Hence, first
of all, SALUS project and its incorporated common data
element based interoperability framework are introduced
in Section 2.1. Afterwards, Section 2.2 outlines the general
design principles of the PMSST on top of a use case scenario
from the SALUS project. And Section 2.3 describes the
implementation and finalizes the Materials and Methods.
2.1. SALUS Project. SALUS aims to create a semantic inter-
operability layer in order to enable the secondary use of
EHR data for clinical research activities. SALUS follows
a common data element based interoperability approach
and uses the semantic MDR to maintain its common data
elements (CDEs). Built upon its abstract CDE definitions,
SALUS exposes a semantic RDF [21] based content model
as its common information model. SALUS project deals
with different content models both in clinical care (i.e.,
HL7/ASTMCCD [22] and CEN/ISO 13606 [23]) and clinical
research domains (i.e., SDTM [24] and OMOP CDM [12])
and harmonizes them in the SALUS common information
model (CIM) [25]. Through its semantic interoperability
layer, SALUS accepts eligibility queries and returns resultant
patient summaries as instances of SALUS CIM.
Several organizations are publishing common data ele-
ment dictionaries and common models in order to solve
the interoperability problem within and between clinical
research and patient care borders. The objective is to provide
a dictionary like the collection of the abstract definitions of
common data elements. Most of the time, these definitions
are published as unstructured text files. Rarely, semistruc-
tured spreadsheets are used to publish the data element spec-
ifications. Health Information Technology Standards Panel
(HITSP) is one of such organizations publishing a library of
common data elements, called HITSP C154: Data Dictionary
[26]. One CDE from this dictionary is “Conditions Problem
Code” which is defined as the code describing the medical
problem according to a specific vocabulary of problems.This
abstract CDE definition can be bound to an implementation










Data retrieval mechanism of the SALUS enabled clinical
research tools has been built on top of the idea of data inter-
operability through federated semantic metadata registries
[27] where the machine-processable CDE definitions play
a crucial role. The CDE based data interoperability approach
introduces a federated system in which the abstract and
machine-processable data element definitions in ISO/IEC
11179 [28] formalism are managed within metadata registries
and can be linked/mapped with each other by using semantic
web technologies. This approach makes a clear distinction
between the abstract definitions and implementation depen-
dent parts of the data elements.
The abstract SALUS common data element (CDE) [29]
definitions published in the scope of SALUS project are
maintained within a semantic MDR. Each CDE has its
extraction specification which can be executed on SALUS
CIM conformant patient data to extract the indicated piece
of information. The extraction specifications of the SALUS
CDEs are SPARQL [30] scripts since SALUS common infor-
mation model (CIM) is RDF based.
As illustrated in Figure 1, different organizations or stan-
dardization bodies can maintain their own CDE specifica-
tions inside the semantic MDR architecture and establish
the semantic links to other CDEs from other systems or
domains. If one abstract CDE set has the access method (so
called extraction specifications such as an XPath or SPARQL
script) to an implementation specific content model (i.e.,
XML based HL7/ASTM CCD or RDF based SALUS CIM),
the semantic link chain among the CDEs can be traversed in
line with the linked data principles and data can be extracted
from the instance conforming to that content model pointed
by the extraction specification. Compared to static message
translation between different specifications, this approach
well integrates with the distributed architectures and does
not need to perform costly operations such as parsing
and message construction. The semantic MDR provides the
necessary functionality together with the interfaces so that
the users and semantic-aware applications can interact with
the system easily.
PMSST is one of the safety analysis tools developedwithin
the scope of the SALUS project. Within this CDE based
data interoperability framework, PMSST retrieves the CDE
definitions from a semantic MDR where any common data
elementmodel can bemaintained according to ISO/IEC 11179
metamodel [28]. Study Data Tabulation Model (SDTM) is
a standard data model for the pharmaceutical companies
while submitting information about clinical studies to FDA.
Pharmaceutical companies like Roche use SDTM variables
for data annotation during their postmarketing surveillance
studies. In our implementation, the registry maintains the
SDTM variables and the SALUS common data elements [29],
and there are semantic links between SDTM and SALUS data
elements as introduced by Sinaci and Laleci Erturkmen [19]
and as illustrated in Figure 1.
Using PMSST, a clinical researcher designs a data schema
(a template) by using SDTM variables on which she writes
scripts (i.e., SAS [31]) for surveillance studies. The system
knows how to extract information from the underlying EHR
data by using the extraction specifications of the CDEs.
Therefore, the researcher is not bound to the data model
of the underlying database; it could be a system providing
HL7/ASTMCCD [22] based patient summaries or anOMOP
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Figure 1: CDE based data interoperability framework through federated semantic metadata registries.
database or any other EHRdatabase aswell as a pharmacoepi-
demiological database. As long as the appropriate extraction
specifications (i.e., XPath [32] scripts for HL7 CCD) are
available, PMSST can extract the necessary information. The
communication with the metadata registry is carried out
through an international interoperability profile, namely, IHE
Data Element Exchange (DEX) profile [20] in which PMSST
implements the metadata consumer role while the semantic
MDR implements the metadata source role.
2.2. Design Considerations. Postmarketing Safety Study Tool
is a web based tool enabling clinical researchers to extract
data from different EHR systems by designing data collection
sets through common data elements. After patient record
is retrieved as a result of an eligibility query, any needed
information can be extracted from the patient record to
populate the data collection set with the help of abstract CDE
definitions used to annotate data collection set definitions.
By means of the underlying interoperability framework [19],
PMSST enables researchers to develop analysis method on
the data collection set schema defined by abstract CDEswith-
out being concerned about the structure of the underlying
data source. The driving force during the design phase of
PMSST is a real world use case identified by the pharmaceu-
tical company Roche in the scope of SALUS project.
2.2.1. PMSST Use Case
Background of the Use Case. Congestive heart failure (CHF)
is a leading cause of hospitalization for patients aged 65 years
and older. CHF is of particular concern in diabetic patients in
whom incidence rates are two to five times greater than those
in the general population. The United Kingdom Prospective
Diabetes Study (UKPDS) estimated incidence rates of 2.3–
11.9 cases per 1000 patient-years in diabetic patients. Several
risk factors of CHF in diabetic patients have been identified.
These include, for example, duration of diabetes, history of
ischemic heart disease, renal function, hypertension, diabetes
treatments, and HbA1C. However, the incidence of CHF in
diabetic patients with a recent acute coronary event is not
fully known. In particular, no estimates of CHF for different
treatment regimens are available in these patients.
Roche is conducting clinical trials in both acute coronary
syndrome (ACS) patients and in ACS patients with diabetes.
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Table 1: Data collection set schema details for the PMSST use case.




Date of acute Coronary
syndrome (ACS) event
(i) ACS event
(ii) Start date of ACS event
(i) MH.MHPTCD
(ii) MH.MHSTDTC 10051592
Date of acute myocardial
infarction
(i) Acute myocardial infarction




Date of unstable angina (i) Unstable angina pectoris(ii) Start date of unstable angina pectoris
(i) MH.MHPTCD
(ii) MH.MHSTDTC 10002388
Had a congestive heart
failure (CHF) before
start of ACS (Y/N)
(i) Congestive heart failure




Had a CHF after start of
ACS (Y/N)
(i) Congestive heart failure




Whilst the trials are blind, it is important to compare the
observed overall incidence rate of an important adverse
event like CHF in the trials with that in similar background
populations. Such a comparison provides a context to the
observed incidence and enables us to identify any potential
safety concerns earlier on (e.g., if the observed incidence in
the trial is greater than the background).
Objective. The objective of this use case is to estimate
incidence rates of CHF in diabetic patients with a recent acute
coronary syndrome (ACS) event considering other diabetic
medications of patients such as type 2 diabetes (T2D) and
related treatment regimens as well. The estimation results
should be stratified based on patient demographics such as
age or gender.
Patient Selection. Identify all patients with a first ACS event
defined by acute myocardial infarction or unstable angina
during the period 2005 to 2011. Include only those patients
who have a minimum of 1-year history prior to the ACS.
Exclude those patients who died within 30 days after the ACS
event. Exclude those patients aged less than 18 at the time of
ACS.The remaining patients define anACS cohort of interest.
For each patient, the STARTDATE is set to 30 days after the
ACS event (so if a patient has an ACS on 5th July 2007, his
start date is set to 4th August 2007). We allow a 30-day delay
to ensure the ACS has stabilized. For each patient define the
LASTDATE as the minimum of date of death or the date the
patient transfers out of the system and can provide no more
data, that is, 31st Dec 2011.
Data Collection Set Definition. For the ACS cohort described
in the previous section, we identified the necessary data that
needs to be gathered as a data collection schema (like a
common information model required for this surveillance
study) composed of several schema items which can be
resembled to the columns of a relational database table.While
some of the data collection set schema items can be extracted
from the EHR data using the extraction specification of
a single SDTM data element, some of them require further
calculations. For instance, whilst the start date of the ACS
event can be extracted in a single operation, we should take
the start date of the ACS event into account to be able
to produce the result for “average systolic blood pressure
(BP) over 12 months before the start of ACS” schema item;
it requires querying of particular measurements within a
particular timeframe and calculation of the mean value.
Table 1 shows a sample of the schema items together
with the corresponding SDTM data elements. In order to
calculate the final results for the schema items, some of the
data elements should be provided with specific MedDRA
[33] codes to indicate the values according to the requested
information which are also indicated in Table 1. For example,
“Date of Acute Myocardial Infarction” is described with
MH.MHPTCD = 10000891, MHSTDTC = ?.
2.2.2. How the Use Case Affected PMSST Design? Patient
selection phase is the execution of the eligibility criteria for
retrieving the data of the defined cohort. For PMSST, this
execution is handled through the semantic interoperability
layer of SALUS. However, this could be any other system like
Sentinel or Query Health [34] fromwhich data is retrieved in
the form of a contentmodel.The data collection set schema is
defined by annotating the schema items with the CDEs that
are already being used in research community, in our case
SDTM data elements. As long as the extraction specifications
of the selected CDEs to that content model are available
from the EHR data sources and reachable with appropriate
links in the semantic MDR, PMSST can perform the same
execution to build data according to the schema defined by
the researcher with the help of the CDEs.
Analyzing the use case, we elicited the key requirements
for PMSST and based the design of the key functionalities of
PMSST on these requirements. During the data collection set
schema definition process, values of particular schema items
might be used in defining other schema items. Therefore,
PMSST provides a flexible variable definition mechanism.
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Figure 2: A snapshot of PMSST while the researcher defines
a data collection set schema. On the right hand side, domains
of SDTM form a circle; if selected, then CDEs of that domain
form the circle. On the left hand side, a schema item “Date
HbA1C Average1YBeforeACS” is created out of 4 SDTM elements.
Below that, a list of other schema items is shown.
PMSST keeps track of the variable definitions and generates
the queries to be applied on the EHR data and organizes their
execution order.
As it can be seen inTable 1, some of the schema items need
further calculation such as average value of blood pressure
measurements, date of the first occurrence of T2D diagnosis,
and last weight value before theACS event.We design PMSST
such that it would present different selection and calculation
options automatically considering the value domain of the
schema item.
Value domains of the used CDEs may be referring to
different terminology/coding systems. For example, while
asking whether a patient has T2D or not, researcher at Roche
uses MHPTCD common data element from the MH domain
of SDTM. Since this data element requires a coded value from
MedDRA, the researcher should easily assign values to such
data elements during her schema design. For this purpose,
PMSST has been integrated with a terminology server so that
it would recommend possible values based on the schema
item through a type-a-head search mechanism.
2.3. SystemDescription. PMSST is aweb based toolwhich can
be used via modern web browsers. It has been implemented
with the latest high performance web technologies incorpo-
rating HTML5 design principles and RESTful client-server
communication. The tool is composed of an eligibility query
execution and a data selection part. Details of the former
are out of the scope of this paper. Upon the execution of an
eligibility query, a cohort of patient data is retrieved in the
form of a content model adopted by the EHR sources. We
claim that the CDE based interoperability implementation
of PMSST can make use of any content model as long as
the appropriate extraction specifications are available for
the abstract CDE definitions within the semantic MDR
framework.
Figure 2 presents the data selection phase of PMSST. The
user can define a data collection set schema at this phase
by using the CDE definitions retrieved from the semantic
MDR. In our implementation, the registry maintains SDTM
variables and SALUS CDE set according to ISO/IEC 11179
metamodel principles. When the user decides to use SDTM,
the object classes (aka domains) are presented to the user
to give a top-down browsing experience. When a domain is
selected, the data elements created out of that object class are
presented to the user. When a CDE is selected, it appears
on the left hand side to create further calculations. Once a
schema item is designed, it is saved and the overall schema
design continues. The user can edit or delete an existing item
anytime during the design phase.
2.3.1. Data Flow between Components. PMSST is composed
of several different components among which a number of
integration mechanisms exist. In Figure 3 the flow of data
between those integrated components is depicted and the
steps of the flow are described in as follows.
(1) The researcher uses a web browser to define the
data collection set schema by using the CDEs. Roche
researchers use SDTM variables in our deployment as
identified in Table 1.
(2) CDEs are maintained in the semantic MDR and
retrieved through the IHE DEX profile. The user
browses the CDEs starting from the object classes in
a top-down fashion.
(3) If the user likes to restrict the value of a selected
data element (i.e., set acute myocardial infarction
to MHPTCD element), possible values can auto-
matically be searched from the terminology server.
PMSST knows in which coding system to look for
the term by analyzing the value domain of the CDE
definition automatically.
(4) After the user completes the schema definition, iden-
tifying each schema item by using abstract CDE def-
initions, the schema definition is sent to the PMSST
engine on the server side.
(5) Eligibility query is sent to the SALUS system and EHR
data of the eligible patients is retrieved in the form of
SALUS common information model.
(6) For each schema item definition, PMSST engine
extracts information from theEHRdata andperforms
necessary calculations to place into the appropriate
location according to the schema definition.
(6.1) Schema is defined by SDTM elements. Semantic
MDR keeps the mappings between SDTM and
SALUS CDEs as presented in Table 2 in the next
section, and SALUS CDEs have the extraction
specifications to access the necessary informa-
tion from the EHR data. CDE definitions, map-
pings, and extraction specifications are retrieved
from the semantic MDR in conformance to the
IHE DEX profile. Since SALUS CIM is an RDF
basedmodel, the extraction specifications of the
SALUS CDEs are SPARQL scripts.
(6.2) If the schema item definition includes a value in
one of its defining CDEs, value analysis should
be done.However, in our deployment, EHRdata
is coded with ICD-9-CM terminology system
BioMed Research International 7
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Figure 3: Step-by-step representation of the data flow between different components. A clinical researcher uses PMSST in order to define a
data collection set schema so that when patient data is retrieved from the underlying EHR source(s), data will be automatically transformed
to that schema.
for patient conditions while SDTM elements
refer to MedDRA or NCI terms. The termi-
nology server includes mappings between these
different coding systems, and PMSST can do
value matching with the help of this terminol-
ogy server.
(7) As a result of these data extraction operations, the
data collection set is populated conforming to the
schema defined by the researcher.
(8) User canwrite analysismethods on top of this schema
independently of the underlying EHR source model.
In our deployment, Roche implements SAS scripts to
do further analysis.
(9) Finally the analysis results are presented to the
researcher.
2.3.2. How Semantic Interoperability Is Achieved through
the Use of CDEs and a Semantic MDR. The CDE based
data interoperability approach lets the PMSST interact with
the semantic MDR through IHE DEX profile and retrieve
abstract CDE definitions. The researcher interacting with
the PMSST uses the data elements that she is used to in
her research domain. The underlying architecture of the
PMSST does not make any message translation between
different contentmodels (i.e., fromSALUSCIMbased patient
summaries to SDTM conformant instances). Instead, the
abstract CDE definitions and their semantic linksmaintained
by the semantic MDR are processed in order to find an
extraction specification to be executed on the content model
to which the EHR data conforms. This clear distinction
between the abstract and implementation dependent parts
of the CDEs enables integrating the CDEs with the semantic
web technologies and linked data principles by using the
semantic MDR.
In our semantic MDR, the links between different sets
of abstract CDE definitions can be established through well-
known knowledge organization systems such as SKOS (i.e.,
skos:exactMatch) or any property can be indicated again with
SKOS (i.e., skos:notation) or other ontological constructs.
PMSST makes use of the abstract CDE definitions of
the SDTM variables retrieved from the semantic MDR. In
order to enable the retrieval of the extraction specifications
given the SDTM variables, we mapped the SDTM elements
to the SALUS CDEs. We implemented an automatic content
model importer on top of the open API of the semanticMDR
for importing the SDTM variables and their mappings to
SALUS CDEs. In this way, although the user defined the data
collection set via SDTM variables, he becomes able to collect
the requested data from the EHRs sources that can provide
the EHRdata of the eligible patients through SALUS common
information model.
In the semantic MDR, SALUS CDEs have also mappings
to HITSP C154 Data Dictionary [26] elements through
skos:exactMatch semantic links. Semantic MDR is capable
of processing these semantic links to establish the links
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Table 2: Mappings of the common data elements: SDTM, SALUS CDE set, and HITSP C154 Data Dictionary.
SDTM SALUS CDE HITSP C154
DM Patient Personal Information
DM.DMSEX Patient.Gender.CD 1.06 Personal Information Gender
MH Patient.Condition.Condition Conditions
MH.MHPTCD Condition.ProblemCode.CD 7.04 Conditions Problem Code
MH.MHSTDTC Condition.TimeInterval.IVLTS 7.01 Conditions Problem Date
between SDTM variables and HITSP C154 elements transi-
tively. Table 2 lists some part of themappings used during the
execution of our implementation.
Although the usage of the tool starts with defining
eligibility criteria and retrieving EHR data according to that
query, our implementation is independent of the content
model according to which the EHR data is shaped. For exam-
ple, if the underlying EHR system can provide HL7/ASTM
CCD based patient summaries, then PMSST can seamlessly
process the data by using the corresponding extraction
specifications retrieved from the semantic MDR. Because
HITSP C154 defines XPath expressions from its CDE defi-
nitions to HL7/ASTM CCD based documents and PMSST
can retrieve the extraction specifications through the HITSP
C154mappings, this time, the extraction specifications would
be XPath expressions and clinical researcher would not be
aware of this. This means that PMSST can automatically
communicate with an EHR system which is capable of
exporting HL7/ASTMCCD based document summaries and
make the data available for clinical research automatically.
3. Results and Discussion
In the context of the SALUS project, PMSST and all related
components have been implemented and deployed on top of
the SALUS interoperability framework integrated with the
central data warehouse of the Lombardy region, Italy. This
regional database includes anonymized data of ∼16 million
patients with over 10-year longitudinal data on the average.
Clinical researchers in Roche are validating the PMSST with
real life use cases, one of which is presented in this paper.
Till the actual deployment within SALUS, we worked with
simulated data to collect further requirements from clinical
researchers and improve the capabilities of PMSST.
For the eligibility criteria defined in the use case intro-
duced in this paper, PMSST retrieved anonymized data
of ∼8000 acute coronary syndrome (ACS) patients from a
population of ∼16 million patients. The definition of the data
collection set schema starts after retrieving the cohort based
on the eligibility criteria. PMSST transforms the retrieved
cohort data to the model defined by the data collection set
schema.The eligibility query execution is not in scope of this
paper.
The researchers in Roche cannot directly see the resultant
data according to the privacy rules of the SALUS project.
Instead, their analysis methods are executed on the returned
dataset and the results of this execution are presented through
the graphical user interface of PMSST. Researchers from
Roche have implemented SAS scripts assuming that in the
end they will have the data represented with SDTM variables,
which they already use in their daily work. However, the data
warehouse of the Lombardy region has a custom schema.
SALUS technical and semantic interoperability solutions
retrieve data from this custom database and transform to
instances of SALUS common information model (CIM).The
CDE based data interoperability approach has enabled the
mappings between the SDTM variables and SALUS CDEs
where the SALUS CDEs have their extraction specifications
(SPARQL scripts in this case). With the help of this architec-
ture, PMSST can extract data from the SALUS CIM based
patient data by using the SDTM variables. Afterwards, the
analysis routines (i.e., SAS scripts) of the clinical researchers
run on the SDTM conformant data.
In order to assess the validity of the data collection
set calculated by PMSST, we have conducted a comparative
analysis. By issuing SQL queries to the data warehouse of
the Lombardy region, we have obtained several statistics
regarding the items in the data collection set and compared
them with the set populated by PMSST. For instance, demo-
graphic analysis on Lombardy region data warehouse shows
that 38.22% of ACS patients are females which is equal to
the percentage of “Female” in “Sex” column of the resultant
PMSST data collection set. Similarly, PMMST calculates
the incidence “Patient died any time after start of ACS” as
34.63% which aligns with the real values calculated in LISPA
data warehouse. These analyses over the items of the data
collection set show that the dataset created by PMSST is
correct compared to the original data and assure us about the
reliability of the results.
One problem we observed during the analysis is that
many items of data collection set defined in Roche use case
were actually empty. For instance, there was no data in any
of the patients regarding the systolic and diastolic blood
pressure measurements, or history of smoking. To deduce
the cause of the problem, we have investigated the LISPA
data warehouse and found out that the available data is not
fully structured. Those empty columns in the resultant data
collection set were also missing in the data warehouse. This
has hindered Roche researchers from full utilization of the
PMSST according to the planned use case. On the other
hand, the records which exist in the data warehouse, such
as the ones related to congestive heart failure (CHF), have
been processed by the tool accurately. Thus, we conclude
that PMSST can be fully exploited once the underlying EHR
source getsmore structured and includesmore data about the
patients.
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3.1. End-User Validation. In order to assess whether PMSST
fulfills the intended use from an end-user point of view or
not, it has been tested and evaluated by real end-users from
Roche in the scope of the SALUS project. An evaluation and
validation framework based on the ISO/IEC 25040 Software
engineering, Software Product Quality Requirements and
Evaluation (SQuaRE) standard has been developed. Accord-
ing to the developed framework, a total of 6 users including
a data analyst and an epidemiologist have taken part in the
evaluation in order to assess the feasibility of conducting a
study over a particular EHR system by using PMSST.
We have built a PMSST specific questionnaire which is
based on the Health IT Usability Evaluation Scale [35] and
provided to the evaluators online. The results obtained from
the questionnaire based evaluation can be summarized as
follows:
(i) PMSST has been a positive addition to postmarketing
safety studies.
(ii) Using PMSSTmakes it easier to define data fields (the
Data Selection tab) to be extracted from the retrieved
patient summaries.
(iii) Using PMSST enables defining data collection fields
and performing data selection more quickly.
Apart from the questionnaire results, the evaluators pro-
vided specific comments addressing the benefits of PMSST
in their studies. Currently Roche conducts safety analysis
studies based on some sample EHR datasets it has. It has
been concluded that having a tool like PMSST which enables
extraction of selected data collection sets of a specified
cohort selection from different EHR systems would be very
beneficial for pharmaceutical companies as it will increase
the size and variability of patient data pools. The data analyst
and the epidemiologist from Roche positively agree on that
PMSST has been successful to achieve its focused objective
and the data provided by the tool is feasible and suitable for
a wider range of observational clinical studies. On the other
hand, they also report that the efficiency of the tool and the
completeness of the data vary depending on the status of
selected EHR data source.
3.2. Current Status and Availability of Software. The deploy-
ment in Lombardy region, Italy, can only serve the SALUS
project partners (i.e., Roche) behind high security firewalls
because of the privacy concerns. For the interested readers,
we prepared a dataset of 50 simulated patients considering
the real world facts that Roche has experienced fromprevious
studies and ongoing work on Lombardy region database. A
package of the deployable software including this simulated
dataset can be requested from the corresponding author.
4. Conclusions
The PMSST, introduced in this paper, enables clinical
researches to define data collection set schemas on which the
postmarketing safety studies will be conducted without being
concerned about the structure of the underlying data sources.
The main benefit of utilization of CDE based interoperability
architecture is the ability of developing surveillance methods
which do not have to be restricted to the data model of
the EHR source: cohort selection and data collection set
definition can be easily done in researchers’ own language
(such as SDTM). Moreover, such an interoperability archi-
tecture allows the data collection operation to be run on
distributed EHRs resources which might be using different
content models to expose patient data.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
The research leading to these results has received funding
from the European Community’s Seventh Framework Pro-
gramme (FP7/2007–2013) under Grant Agreement no. ICT-
287800, SALUS project (Scalable, Standard Based Interop-
erability Framework for Sustainable Proactive Post Market
Safety Studies).
References
[1] M. Hauben and A. Bate, “Data mining in pharmacovigilance,”
Pharmaceutical Data Mining: Approaches and Applications for
Drug Discovery, vol. 6, article 341, 2009.
[2] G. N. Norén, R. Orre, A. Bate, and I. R. Edwards, “Duplicate
detection in adverse drug reaction surveillance,” Data Mining
and Knowledge Discovery, vol. 14, no. 3, pp. 305–328, 2007.
[3] M. Suling and I. Pigeot, “Signal detection andmonitoring based
on longitudinal healthcare data,”Pharmaceutics, vol. 4, no. 4, pp.
607–640, 2012.
[4] J. C. Nelson, A. J. Cook, O. Yu, S. Zhao, L. A. Jackson, and B.
M. Psaty, “Methods for observational post-licensure medical
product safety surveillance,” Statistical Methods in Medical
Research, vol. 24, no. 2, pp. 177–193, 2015.
[5] B. L. Strom, S. E. Kimmel, and S. Hennessy, “The future of phar-
macoepidemiology,” in Textbook of Pharmacoepidemiology, pp.
447–454, 2013.
[6] R. Platt, M. Wilson, K. A. Chan, J. S. Benner, J. Marchibroda,
and M. McClellan, “The new sentinel network—improving the
evidence of medical-product safety,” The New England Journal
of Medicine, vol. 361, no. 7, pp. 645–647, 2009.
[7] M. Hauben and A. Bate, “Decision support methods for the
detection of adverse events in post-marketing data,” Drug
Discovery Today, vol. 14, no. 7-8, pp. 343–357, 2009.
[8] SALUS Consortium, “SALUS: scalable, standard based inter-
operability framework for sustainable proactive post market
safety studies. A brief overview of SALUS interoperability
approach,” Whitepaper, 2012, http://www.salusproject.eu/docs/
SALUSwhite paper-Final.pdf.
[9] P. Coorevits, M. Sundgren, G. O. Klein et al., “Electronic health
records: new opportunities for clinical research,” Journal of
Internal Medicine, vol. 274, no. 6, pp. 547–560, 2013.
[10] R. E. Behrman, J. S. Benner, J. S. Brown, M. McClellan, J.
Woodcock, and R. Platt, “Developing the sentinel system—a
national resource for evidence development,”The New England
Journal of Medicine, vol. 364, no. 6, pp. 498–499, 2011.
10 BioMed Research International
[11] M. A. Robb, J. A. Racoosin, R. E. Sherman et al., “The US
food and drug administration’s sentinel initiative: expanding
the horizons of medical product safety,” Pharmacoepidemiology
and Drug Safety, vol. 21, no. 1, pp. 9–11, 2012.
[12] Foundation for National Institutes of Health, Observational
Medical Outcomes Partnership (OMOP), http://omop.org/.
[13] National Institute for Health Research, Clinical Practice
Research Datalink (CPRD), http://www.cprd.com/.
[14] University College London, The Health Improvement Network
(THIN), 2013, http://www.ucl.ac.uk/pcph/research-groups-
themes/thin-pub.
[15] Translational Research and Patient Safety in Europe (TRANS-
FoRm), 2014, http://www.transformproject.eu/.
[16] Electronic Health Record Systems for Clinical Research
(EHR4CR), 2014, http://www.ehr4cr.eu/.
[17] F. DeStefano, “The vaccine safety datalink project,” Pharma-
coepidemiology and Drug Safety, vol. 10, no. 5, pp. 403–406,
2001.
[18] S. N. Murphy, G. Weber, M. Mendis et al., “Serving the enter-
prise and beyond with informatics for integrating biology and
the bedside (i2b2),” Journal of the AmericanMedical Informatics
Association, vol. 17, no. 2, pp. 124–130, 2010.
[19] A. A. Sinaci and G. B. Laleci Erturkmen, “A federated seman-
tic metadata registry framework for enabling interoperability
across clinical research and care domains,” Journal of Biomedical
Informatics, vol. 46, no. 5, pp. 784–794, 2013.
[20] Integrating the Healthcare Enterprise (IHE), Data Element
Exchange (DEX) Profile, Trial Implementation, 2013, http://
www.ihe.net/uploadedFiles/Documents/QRPH/IHE QRPH
Suppl DEX.pdf.
[21] World Wide Web Consortium (W3C), Resource Description
Framework (RDF), WorldWideWeb Consortium (W3C), 2014,
http://www.w3.org/RDF/.
[22] Health Level 7 (HL7)/American Society for Testing and
Materials (ASTM), Continuity of Care Document (CCD), 2014,
http://www.hl7.org/documentcenter/public temp DC68F8CB-
1C23-BA17-0CB6B9727B87B502/pressreleases/20070212.pdf.
[23] The European Committee for Standardization (CEN) and
International StandardizationOrganization (ISO),Health Infor-
matics—Electronic Health Record Communication (EN 13606),
The European Committee for Standardization (CEN), Interna-
tional Standardization Organization (ISO), 2008.
[24] Clinical Data Interchange Standards Consortium (CDISC),
Study Data Tabulation Model (SDTM), 2014, http://www.cdisc
.org/sdtm.
[25] M. Yuksel, S. Gonul, G. B. L. Erturkmen et al., “Demonstration
of the SALUS semantic interoperability framework for case
series characterization studies,” SWAT4LS, 2013.
[26] Healthcare Information Technology Standards Panel (HITSP),
C154: HITSPData Dictionary, 2014, http://www.hitsp.org/Con-
structSet Details.aspx?&PrefixAlpha=4&PrefixNumeric=154.
[27] A. A. Sinaci, Data interoperability through federated semantic
metadata registries [Ph.D. thesis], Middle East Technical Uni-
versity, Ankara, Turkey, 2014.
[28] InternationalOrganization for Standardization (ISO) and Inter-
national Electrotechnical Commission (IEC), ISO/IEC 11179:
Information Technology—Metadata Registries (MDR) Parts 1–6,
International Organization for Standardization (ISO), Interna-
tional Electrotechnical Commission (IEC), 2nd edition, 2014.
[29] SALUS Deliverable 4.2.2—SALUS Common Set of Data
Elements for Post Market Safety Studies—R2, http://www
.salusproject.eu/docs/D4.2.2.pdf.
[30] World Wide Web Consortium (W3C), SPARQL Query Lan-
guage for RDF, 2014, http://www.w3.org/TR/rdf-sparql-query/.
[31] SAS Institute Inc, SAS 9.2 Language Reference: Concepts, SAS
Institute Inc., Cary, NC, USA, 2nd edition, 2010.
[32] World Wide Web Consortium (W3C), XML Path Language
(Xpath), 2014, http://www.w3.org/TR/xpath/.
[33] International Conference on Harmonisation (ICH), Medical
Dictionary for Regulatory Activities (MedDRA), 2014, http://
www.meddra.org/.
[34] J. G. Klann, M. D. Buck, J. Brown et al., “Query health:
standards-based, cross-platform population health surveil-
lance,” Journal of the American Medical Informatics Association,
vol. 21, no. 4, pp. 650–656, 2014.
[35] P.-Y. Yen, D. Wantland, and S. Bakken, “Development of
a customizable health IT usability evaluation scale,” AMIA
Annual Symposium Proceedings, vol. 2010, pp. 917–921, 2010.

















Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Antibiotics
International Journal of
Toxicology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Stroke
Research and Treatment
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Drug Delivery
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in 
Pharmacological 
Sciences
Tropical Medicine
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Medicinal Chemistry
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Addiction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Emergency Medicine 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Autoimmune 
Diseases
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Anesthesiology 
Research and Practice
Scientifica
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Pharmaceutics
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
